Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
MWN-AI** Summary
Telix Pharmaceuticals Limited has made a significant advancement in the treatment of recurrent glioblastoma, an aggressive form of brain cancer, by dosing the first patient in its Phase 3 IPAX-BrIGHT trial for TLX101-Tx (¹³¹I-iodofalan). This pivotal trial, conducted at Austin Health in Melbourne, Australia, is the first of its kind for a radiopharmaceutical therapy targeting this challenging condition. TLX101-Tx aims to evaluate its safety and efficacy when combined with chemotherapy (lomustine) versus chemotherapy alone in patients experiencing their first disease recurrence.
Glioblastoma treatments have remained largely stagnant, with only two FDA-approved drugs in the last 25 years. TLX101-Tx stands out by targeting the L-type amino acid transporter 1 (LAT1), facilitating the drug's entry through the blood-brain barrier directly into the tumor. Previous studies showed promising results, such as a median overall survival (OS) of 13 months from treatment initiation documented in the IPAX-13 trial.
The IPAX-BrIGHT trial is a multicenter and open-label study aimed at enrolling patients with confirmed recurrent glioblastoma. Telix's commitment is underscored by an early access program in Europe, which has already treated 18 patients, demonstrating the potential clinical utility of TLX101-Tx.
Professor Hui Gan, a key figure in the trial, expressed enthusiasm about exploring this innovative therapy in the context of high unmet medical needs. Telix's Group Chief Medical Officer, Dr. David N. Cade, noted that this registration-enabling study represents a hopeful advancement for neuro-oncology, potentially offering a first-in-class treatment option for glioblastoma patients.
MWN-AI** Analysis
Telix Pharmaceuticals’ announcement regarding the commencement of dosing the first patient in the Phase 3 IPAX-BrIGHT trial of TLX101-Tx represents a significant milestone in the oncology landscape, particularly for glioblastoma treatment. Given the historical lack of effective therapies for recurrent glioblastoma, this pivotal trial could position Telix at the forefront of innovative cancer treatments, making it a compelling investment opportunity.
The trial's focus on TLX101-Tx, which utilizes a novel mechanism targeting LAT1 to cross the blood-brain barrier, provides a potentially groundbreaking approach to treatment where traditional options have failed. The reported median overall survival rates from previous studies (13 months from treatment initiation and 23 months from diagnosis) suggest encouraging efficacy, enhancing the pharmaceutical's profile. This diversification in therapeutic strategy not only emphasizes Telix's potential for significant clinical advancement but also reflects a growing market demand for innovative solutions in oncology.
As Telix progresses through IPAX-BrIGHT, investors should monitor key milestones such as patient enrollment rates, interim data releases, and potential FDA submission timelines. Positive trial outcomes could catalyze stock performance, especially as expectations build around TLX101-Tx's introduction to the market. Furthermore, Telix has already initiated early access programs in Europe, confirming the clinical utility and urgency surrounding the therapeutic, which could bolster market confidence.
From a market perspective, Telix’s strategic initiatives reflect foundational growth not just in product potential but also in establishing strong partnerships and aligning its vision with the pressing needs within neuro-oncology. Investors would do well to evaluate TLX as a long-term hold, especially considering its innovative pipeline and the pressing demands of recurrent glioblastoma treatment where little to no effective options currently exist.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial1, marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, an aggressive form of brain cancer.
The patient was dosed at Austin Health in Melbourne, Australia, under the supervision of Professor Hui Gan. IPAX BrIGHT is assessing the safety and efficacy of TLX101-Tx in combination with chemotherapy (lomustine), compared to chemotherapy alone. The global, multicenter, open-label study will enroll patients with radiographically confirmed recurrent glioblastoma at first recurrence.
Telix’s commitment to advancing care for patients with glioblastoma is driven by the significant unmet need in this space. In the past 25 years, only two drugs have been approved by the United States Food and Drug Administration (FDA) for glioblastoma2, and no standard treatment currently exists for recurrent disease. Patients therefore face limited treatment options after initial therapy. TLX101-Tx offers a novel approach by targeting the L-type amino acid transporter 1 (LAT1), a transporter that enables the radiopharmaceutical to cross the blood-brain barrier and delivers therapy directly to the tumor.
IPAX BrIGHT expands upon promising data from earlier trials in the recurrent glioblastoma setting, including IPAX-13, which reported a median overall survival (OS) of 13 months from the initiation of treatment with TLX101-Tx, or 23 months from initial diagnosis4. Preliminary results from the IPAX-Linz investigator-initiated trial of TLX101-Tx were consistent and confirmatory to IPAX-1, with a median OS of 12.4 months from initiation of treatment and 32.2 months from initial diagnosis5. Beyond the clinical trial setting, an early access program for TLX101-Tx in Europe has dosed 18 patients at first recurrence or later, further establishing the clinical utility of TLX101-Tx.
Professor Gan, Director of Cancer Clinical Trials at Austin Health, said, “Based on the prior safety profile and early efficacy data for TLX101-Tx in the IPAX-1 and IPAX-Linz studies, I am pleased to continue to explore this therapeutic modality in the first radiopharmaceutical pivotal trial in recurrent glioblastoma, where there are currently few effective treatment options.”
Dr. David N. Cade, Group Chief Medical Officer, Telix, added, “Through the IPAX BrIGHT trial, we aim to offer a new option for patients affected by glioblastoma. This registration-enabling study represents a major step forward in our mission to improve therapeutic options in neuro-oncology. With very limited innovation in treatment in recent decades, TLX101-Tx has the potential to become a first-in-class therapy that meaningfully improves patient outcomes.”
The IPAX BrIGHT study has received regulatory approval in Australia, Austria, Belgium and the Netherlands with approval being sought in additional jurisdictions. Telix’s investigational PET6 imaging agent for glioma, TLX101-Px (floretyrosine F 18) will be used for patient selection in IPAX BrIGHT, as well as assessing metabolic tumor response according to PET RANO 1.07.
About TLX101-Tx
TLX101-Tx (131I-iodofalan) is a systemically administered radiopharmaceutical therapy that targets L-type amino acid transporter 1 (LAT1), which is typically over-expressed in glioblastoma. TLX101-Tx utilizes a small molecule approach due to the need to cross the blood brain barrier, the normal protective barrier that prevents many potential drug candidates entering the brain. In addition to the IPAX-1 and IPAX-Linz studies, TLX101-Tx is also under investigation in the IPAX-2 Phase 1 study in combination with post-surgical standard of care treatment in patients with newly diagnosed glioblastoma8. TLX101-Tx has received orphan drug designation in the U.S. and Europe for the treatment of glioma. TLX101-Tx and TLX101-Px have not received a marketing authorization in any jurisdiction.
About glioblastoma
Glioblastoma (GBM), is a high-grade glioma and the most common and aggressive form of primary brain cancer, with approximately 22,000 new cases diagnosed annually in the U.S.9.?The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients10, with an expected survival duration of 12-15 months from diagnosis11.
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
| Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com | Telix Investor Relations (U.S.)? Ms. Annie Kasparian? Director Investor Relations and Corporate Communications? annie.kasparian@telixpharma.com | Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com |
Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
1 ClinicalTrials.gov ID: NCT07100730.
2 Temozolomide approved in 2005 and Bevacizumab in 2009.
3 ClinicalTrials.gov ID: NCT03849105.
4 Pichler et al. Neurooncol Adv. 2024. https://doi.org/10.1093/noajnl/vdae130
5 Telix ASX disclosure April 16, 2025. Date presented by Professor Josef Pichler at the Nuclear Medicine and Neurooncology (NMN) Symposium in Vienna (Austria), May 2025.
6 Positron emission tomography.
7 Response Assessment in Neurooncology practice guidelines for the clinical use of PET imaging in gliomas.
8 ClinicalTrials.gov ID: NCT05450744.
9 Ostrom 2022, CBTRUS (Central Brain Tumor Registry of the United States) Statistical Report.
10 Park et al. Journal of Clinical Oncology. 2010.
11 Ostrom et al. Neuro Oncol. 2018.
FAQ**
How is Telix Pharmaceuticals Limited (TLX) leveraging its research in Melbourne to address the unmet medical needs of glioblastoma patients during the IPAX BrIGHT trial?
What specific regulatory approvals has Telix Pharmaceuticals Limited (TLX) received for the TLX101-Tx therapy in different jurisdictions, including Australia and Indianapolis?
What potential impacts does Telix Pharmaceuticals Limited (TLX) anticipate from the Phase 3 IPAX BrIGHT trial on the future treatment options for glioblastoma patients?
In what ways could the clinical outcomes from Telix Pharmaceuticals Limited's (TLX) TLX101-Tx trial transform the landscape of neuro-oncology therapy in markets like Melbourne and Indianapolis?
**MWN-AI FAQ is based on asking OpenAI questions about Telix Pharmaceuticals Limited (NASDAQ: TLX).
NASDAQ: TLX
TLX Trading
-1.16% G/L:
$9.39 Last:
206,785 Volume:
$9.50 Open:
